Heart disease is the leading cause of death
|
|
- Mildred Wheeler
- 6 years ago
- Views:
Transcription
1 ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population and requires immediate identification and management to prevent the poor outcomes associated with therapeutic delays. Although some patients have the option of either a conservative or invasive strategy to address ACS, invasive percutaneous coronary intervention (PCI) has become an attractive option in many patients. Both medical management and the PCI procedure require the use of antiplatelet agents, as well as antithrombotic therapy, during hospitalization and after discharge to prevent a recurrence of ischemic events. This review will discuss the therapeutic options in ACS for those undergoing medical and invasive management, and will specifically address important issues in the use of antiplatelet agents in these patients. (Adv Stud Med. 2007;7(17): ) Heart disease is the leading cause of death in the United States, and more than 79 million American adults are affected by some form of cardiovascular disease. 1 Coronary heart disease (CHD) is a particularly common problem that affects more than 15 million US individuals, 7.9 million of whom have already suffered from myocardial infarction (MI) and 8.9 million of whom suffer from angina pectoris, or chest pain, stemming from underlying CHD. 1 The high prevalence of CHD in the US population is linked to important common risk factors in Americans, including hypertension, dyslipidemia, smoking, diabetes, and overweight/obesity. 2 Patients with CHD are at risk of developing an acute coronary syndrome (ACS), a condition that has the potential to carry a great risk of morbidity and mortality. Therefore, it is critical that primary care physicians are familiar with ACS, current management options, and the challenges that clinicians face in making daily therapeutic decisions in patients presenting with the condition. ACS: AN OVERVIEW *Associate Professor of Medicine, Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts. Address correspondence to: Christopher P. Cannon, MD, Associate Professor of Medicine, Harvard Medical School, Brigham and Women s Hospital, Cardiovascular, 75 Francis Street, Boston, MA cpcannon@partners.org. The term ACS refers to a syndrome with a variety of causes, all of which result in an imbalance between oxygen supply and demand to the heart. 2 The ACS disease spectrum most typically encompasses different etiologies of ischemia stemming from arterial blockage related to CHD, generally classified as ST-segment elevation MI (STEMI) or unstable angina (UA)/non ST-segment elevation MI (NSTEMI). The presence of CHD results in the development of atherosclerotic plaques on the arterial wall that can rupture, resulting in a partial or total occlusion of the affected blood vessels and a reduction in the amount of oxygen supplied to the heart. In STEMI, there is a sudden disruption of the atherosclerotic plaque. This event precipitates a cascade of 540 Vol. 7, No. 17 n December 2007
2 events, in part due to the exposure of substances in the plaque to the blood supply, which result in platelet activation, aggregation, and adhesion; thrombin generation; and the development of a thrombus. This thrombus can entirely block the blood supply to the heart and quickly result in myocardial necrosis. 3 This chain of events puts the patient at a significant risk of death, and therefore, it is critical to rapidly identify and manage patients suffering from this syndrome. Similar to STEMI, a UA/NSTEMI event most typically occurs when a plaque becomes disrupted as a result of arterial inflammation. This event results in a release of platelet aggregates and other substances from the disrupted plaque, but does not usually cause complete occlusion of the artery. 2 Nevertheless, UA/NSTEMI also carries an increased risk of complications and death if not rapidly identified and treated. 2 Although the incidence of STEMI has decreased over the past 2 decades, the incidence of UA/NSTE- MI is rising, and efforts are under way to modify UA/NSTEMI risk and improve outcomes in individuals who suffer from these events. 2 MORBIDITY AND MORTALITY RISK The high rate of CHD and consequent ACS carries a heavy toll in terms of morbidity and mortality. The long-term consequences of ACS can include a higher risk of heart failure, a recurrence of ACS events, and early mortality. 2,3 The high risk of poor outcomes in ACS is most striking in patients who do not present with chest pain or other typical symptoms and therefore, receive late treatment or a lack of ideal therapy. An analysis from the Global Registry of Acute Coronary Events (GRACE) found that patients with ACS who did not present with chest pain or other typical symptoms experienced more complications during their hospital stay. Furthermore, almost 20% of patients with STEMI without chest pain died during hospitalization. 4 Overall, CHD was responsible for 1 in 5 US deaths in 2004 and remains the single most common cause of death in men and women. 1 The risk of morbidity and death from ACS due to underlying CHD highlights the importance of early diagnosis and management with the ideal therapeutic strategy in patients presenting with symptoms suggestive of ACS. THERAPEUTIC OPTIONS One of the most important aspects of care in ACS is the rapid identification of UA/NSTEMI and STEMI in PRACTICE RECOMMENDATIONS FOR ACS The ACC/AHA guidelines for the management of both UA/NSTEMI and STEMI recommend that patients presenting with suspected ACS receive prompt care that includes ECG and blood marker evaluation. The guidelines emphasize risk stratification as an important aspect of the initial evaluation to guide physicians in choosing between medical (drugbased) and invasive (interventional) strategies for care. The TIMI and GRACE risk scoring systems are both recommended as valid tools for stratifying risk in patients with ACS. The choice of primary PCI versus fibrinolysis in STEMI should be selected with careful attention to the timing from onset of symptoms to hospital presentation, the immediate availability of catheterization services, and the experience of the personnel and center providing invasive care. In UA/NSTEMI, the choice of an invasive versus a conservative strategy is based on the patient s relative level of risk. Patients undergoing PCI should receive pre-pci administration of antiplatelet therapy with aspirin and a thienopyridine, as well as the periprocedural addition of antithrombotic therapy with unfractionated heparin, low-molecular-weight heparin, or bivalirudin. The addition of a glycoprotein IIb/IIIa inhibitor is also warranted in high-risk patients. Sources: Anderson JL, Adams CD, Antman EM, et al. J Am Coll Cardiol. 2007;50:e1-e157. Antman EM, Anbe DT, Armstrong PW, et al. Circulation. 2004;110:e82-e292. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. Circulation. 2006;113:e166-e286. Web sites: Strength of Evidence: Panels composed of experts in the prevention, detection, and management of cardiovascular disease developed the ACC/AHA guidelines for the management of UA/NSTEMI, the ACC/AHA guidelines for the management of STEMI, and the ACC/AHA/ Society of Cardiovascular Angiography and Interventions guidelines for PCI. These recommendations are based on the weight of available clinical evidence and are considered to provide a high degree of benefit with a low potential for risk. Johns Hopkins Advanced Studies in Medicine n 541
3 patients presenting with suspicious symptoms. 2,3 The American College of Cardiology/American Heart Association (ACC/AHA) guidelines for both UA/NSTEMI and STEMI emphasize that patients with chest pain consistent with ACS, which is generally characterized as severe pain or discomfort over the chest or radiating down the left arm, should be triaged immediately to receive an electrocardiogram (ECG) and evaluation of blood markers of cardiac injury to arrive at a diagnosis of UA/NSTEMI or STEMI. 2,3 Once an ACS diagnosis has been established, there are 2 established routes of care. For STEMI, depending on the timing between the onset of symptoms and presentation in the urgent care setting, and the availability of a catheterization facility, physicians decide on a course of either pharmacologic reperfusion (ie, fibrinolysis) or primary percutaneous coronary infusion (PCI). More rapid reperfusion achieved with either strategy is associated with improved outcomes. For UA/NSTEMI, a choice of an invasive strategy, usually within 24 to 48 hours of presentation, or a conservative approach is taken based on the patient s relative degree of risk. Medical management proceeds with an established combination of antiplatelet and antithrombotic drugs, whereas an invasive or interventional strategy also includes a combination of antiplatelet and antithrombotic medications, administered before the procedure, followed by angiography and revascularization with the placement of a stent to prevent future reocclusion of the artery at the location of the atherosclerotic plaque. MEDICAL MANAGEMENT Current antithrombotic pharmacotherapy consists of treatment with a combination of antiplatelet agents, including aspirin and a thienopyridine (clopidogrel), antithrombotic therapy with unfractionated heparin or low-molecular-weight heparin (or, more recently, a direct thrombin inhibitor or a factor Xa inhibitor), and the addition of a glycoprotein IIb/IIIa inhibitor in high-risk patients and in those undergoing PCI. 2,3 In patients diagnosed with STEMI, primary PCI is generally preferred, if available. The ACC/AHA guidelines suggest that fibrinolysis is favored in STEMI when prolonged transport to another facility is anticipated or the time between hospital arrival and the interventional procedure (door-to-balloon time) is anticipated to be greater than 90 minutes. 3 In patients with UA/NSTEMI, an invasive strategy is preferred in patients classified as higher risk after an evaluation of symptoms, ECG, cardiac biomarkers, comorbidities, and medical history. 2 The Thrombolysis in Myocardial Infarction (TIMI) and GRACE risk stratification tools are both suggested by the guidelines to assess the risk of cardiac events and mortality in ACS, and are used to choose between a conservative and interventional strategy in UA/NSTEMI. 2 INVASIVE MANAGEMENT The decision to proceed with an interventional procedure in many patients with ACS is based on multiple trials that have demonstrated improved outcomes with an invasive strategy. 3,5 In patients with STEMI with immediate access to a catheterization facility, primary PCI is often the regimen of choice. However, the ACC/AHA/Society of Cardiovascular Angiography and Interventions guidelines for PCI stress that the value of PCI over medical management has not been established when performed by an operator who performs fewer than 75 cases per year or in low-volume centers ( cases/year). 6 The PCI procedure requires the preprocedural administration of antiplatelet therapy with aspirin and a thienopyridine, as well as the periprocedural addition of antithrombotic therapy with unfractionated heparin, low-molecular-weight heparin, or bivalirudin to reduce the risk of further thrombus generation from the ruptured plaque. 3,6 The addition of a glycoprotein IIb/IIIa inhibitor is also routinely used to more effectively inhibit platelet aggregation. The direct thrombin inhibitor bivalirudin is an acceptable antithrombotic alternative to heparin therapy, particularly in those who have a contraindication to heparin therapy because of documented heparin-induced thrombocytopenia. 2,3,6 Post-PCI antiplatelet management is also critical, particularly in patients whose PCI procedures include the placement of a stent, as antiplatelet therapy is required to reduce to risk of restenosis. Although some debate has surrounded the ideal time frame for pre- PCI initiation of antiplatelet therapy and the length of follow-up therapy after the procedure, data from the PCI-CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events), the CREDO (Clopidogrel for the Reduction of Events During Observation), and the PCI-CLARITY (PCI- Clopidogrel as Adjunctive Reperfusion Therapy) trials 542 Vol. 7, No. 17 n December 2007
4 all revealed that antiplatelet therapy provides the greatest benefit when initiated at least 6 hours before the PCI procedure and continued for a period of 1 year after the procedure. 7-9 A higher dose of clopidogrel can shorten the pretreatment period to 2 hours to achieve a high level of platelet inhibition. Clinical guidelines now reflect these findings and recommend that ongoing antiplatelet management with both aspirin and a thienopyridine continue for at least 1 month and ideally for up to 1 year after the procedure to reduce the risk of further thrombotic events. For patients with drug-eluting stents, at least 1 year of thienopyridine therapy is recommended. 2,3,6,10,11 CURRENT THERAPEUTIC ISSUES The management of patients with ACS has been considerably advanced with the advent of new pharmacologic therapies in medical and invasive strategies, but important issues still exist with the use of these agents in daily practice. ANTIPLATELET RESISTANCE Antiplatelet resistance is increasingly recognized as an important underlying issue that can affect a patient s response to therapy. The degree of documented antiplatelet resistance often varies considerably between patients and depends on the type of platelet function test used, 11 but a variable response to both aspirin and clopidogrel have been documented in healthy subjects and those undergoing PCI. 12,13 Antiplatelet resistance has been identified as a causative factor contributing to the residual risk of periprocedural and postprocedural events that is relatively common in patients undergoing PCI for ACS In one study that evaluated clopidogrel response in patients with ACS undergoing PCI with a variety of platelet function tests, investigators reported a wide variability in response to clopidogrel therapy, with up to 25% of patients exhibiting clopidogrel resistance. Additionally, 88% of subsequent ischemic events during a 6-month follow-up period occurred in patients who had exhibited clopidogrel resistance, suggesting a link between clopidogrel resistance and a greater risk of postprocedural events. 15 Based on these findings, researchers have suggested that patients undergoing PCI should be evaluated for antiplatelet resistance, at least to assist in risk stratification. 12 In addition, the emergence of new antiplatelet options may help physicians guide therapy when resistance to aspirin and clopidogrel is observed. GUIDELINE ADHERENCE It is also important to note that a failure to follow established evidence-based guidelines for the management of patients with ACS who are undergoing PCI, 2,3,6 especially with respect to the length of follow-up antiplatelet therapy, also may impact outcomes and result in excessive thrombotic risk. Although physicians should carefully evaluate patients for bleeding risk, it is important to consider up to 1 year of antiplatelet therapy with a thienopyridine, such as clopidogrel, in patients who have undergone PCI. OPPORTUNITIES TO IMPROVE OUTCOMES There is no doubt that therapeutic options in ACS have greatly expanded in the past decade with the introduction of agents such as low-molecular-weight heparins and other anticoagulants, glycoprotein IIb/IIIa inhibitors, and clopidogrel. The wealth of research in ACS and PCI continues to bring new concepts to light for improving outcomes and reducing the residual risk that is still observed after patients receive interventional procedures. LIPID LOWERING IN ACS Although lipid reduction with the use of statin agents has traditionally been considered a long-term management strategy, it is now becoming clear that the use of statin therapy in the acute setting may improve outcomes in ACS due to effective reductions in lowdensity lipoprotein cholesterol (LDL-C) and C-reactive protein, a marker of systemic inflammation. The MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) study randomized 3086 patients with NSTEMI to begin atorvastatin 80 mg or placebo within 24 to 96 hours of hospital admission. During a follow-up period of 4 months, patients receiving atorvastatin had a 16% lower risk of the primary composite endpoint of death, nonfatal acute MI, cardiac arrest requiring resuscitation, or recurrent symptomatic myocardial ischemia requiring emergency rehospitalization (P =.048). Patients receiving atorvastatin experienced a 42% reduction in mean LDL-C, declining from 124 mg/dl to 72 mg/dl during treatment. 16 Johns Hopkins Advanced Studies in Medicine n 543
5 The PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) TIMI-22 trial investigated the use of either standard-dose statin therapy (pravastatin 40 mg/day) or high-dose statin therapy (atorvastatin 80 mg/day) in 4162 patients with ACS who were randomized within 10 days of hospitalization for ACS and were followed for a period of up to 2 years. Those receiving the intensive statin regimen had a 16% reduction in the composite endpoint of allcause mortality, MI, recurrent angina requiring hospitalization, revascularization ( 30 days after randomization), and stroke (P =.005). 17 The A to Z (Aggrastat to Zocor) trial likewise reported a benefit with intensive statin therapy after 4 months posthospitalization, but failed to demonstrate an early benefit. 17 However, an analysis of data from the PROVE-IT and A to Z trials concluded that the results of both studies demonstrate the benefit of early intensive statin therapy. 18 The administration of intensive statin therapy has a favorable safety profile 17,18 and is an attractive therapeutic option in ACS. NEW ANTIPLATELET OPTIONS New antiplatelet therapies have the potential to further expand treatment options, especially in light of the problems encountered with resistance to aspirin and clopidogrel. The effects of prasugrel, a novel thienopyridine, were recently evaluated in the TRI- TON (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel) TIMI-38 trial. A population of patients with ACS (UA/NSTEMI and STEMI) scheduled for PCI was randomized to receive either clopidogrel (300-mg loading dose followed by 75-mg/day maintenance dose) or prasugrel (60-mg loading dose followed by 10-mg/day maintenance dose). All patients received aspirin therapy in addition to the thienopyridine. Over a median treatment period of 12 months, those receiving prasugrel had a significantly lower rate of the primary composite endpoint of cardiovascular death, MI, or stroke compared with those receiving clopidogrel (12.1% vs 9.9%, P =.0004). In addition, a greater than 50% reduction in stent thrombosis was observed. However, prasugrel was associated with a significantly higher rate of major bleeds (2.4% vs 1.8%, P =.03; Figure), 19 and investigators suggested that prasugrel should not be used in patients with a history of cerebrovascular accidents or transient ischemic attack. 19 CONCLUSIONS Patients presenting with ACS benefit from recent advances in management strategies, including the advent of thienopyridine antiplatelet drugs that reduce the risk of periprocedural events during PCI and improve long-term outcomes after hospital discharge. Although challenges remain in identifying patients who may exhibit antiplatelet resistance, new therapeutic options are emerging that may represent viable alternatives in patients who exhibit resistance. Overall, antiplatelet agents, along with antithrombotic agents and glycoprotein IIb/IIIa inhibitors, have greatly improved outcomes when used in accordance with ACS guidelines. The high risk of poor outcomes and mortality in unrecognized or undertreated ACS highlights the continuing need to emphasize early identification and effective management of ACS in daily practice. Figure. Efficacy and Safety Findings in the TRITON TIMI-38 Trial CABG = coronary artery bypass graft; CV = cardiovascular; HR = hazard ratio; MI = myocardial infarction; NNH = number needed to harm; NNT = number needed to treat; TIMI = Thrombolysis in Myocardial Infarction; TRITON = Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel. Reprinted with permission from Wiviott et al. N Engl J Med. 2007;357: Vol. 7, No. 17 n December 2007
6 REFERENCES 1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST- Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1-e Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82-e Brieger D, Eagle KA, Goodman SG, et al. Acute coronary syndromes without chest pain: an underdiagnosed and undertreated high-risk group. Insights from the Global Registry of Acute Coronary Events (GRACE). Chest. 2004;126: Boden WE, O Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356: Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166-e Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358: Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288: Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294: Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO) TIMI 26 trial. Circulation. 2005;111: Wallentin L. Prevention of cardiovascular events after acute coronary syndrome. Semin Vasc Med. 2005;5: Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation. 2004;109: Wiviott SD. Clopidogrel response variability, resistance, or both? Am J Cardiol. 2006;98:S18-S Michos ED, Ardehali R, Blumenthal RS, et al. Aspirin and clopidogrel resistance. Mayo Clin Proc. 2006;81: Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109: Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285: Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46: Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipidlowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006;113: Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357: Johns Hopkins Advanced Studies in Medicine n 545
CLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationAcute Coronary syndrome
Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationAcute coronary syndromes (ACS), including unstable
n report n Acute Coronary Syndromes: Morbidity, Mortality, and Pharmacoeconomic Burden Daniel M. Kolansky, MD Abstract Acute coronary syndromes (ACS), which include unstable angina and myocardial infarction
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationJournal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.
Journal of the American College of Cardiology Vol. 54, No. 25, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.005
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationAcute coronary syndrome (ACS) is an
OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationDIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN
DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationNon ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
More informationSTEMI Presentation and Case Discussion. Case #1
STEMI Presentation and Case Discussion Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando, Florida September 17 th,
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationEarly and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 51, No. 21, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.04.002
More informationLife Science Journal 2016;13(5) Acute Coronary Syndrome Process In Geriatric Population: One Year Follow-Up Study
Acute Coronary Syndrome Process In Geriatric Population: One Year Follow-Up Study Samim Emet, MD 1, Fatih Akdogan 2, Yucel Arman 2, Murat Kose, MD 3, Basak Saracoglu, MD 4, Tufan Tukek, MD 3 1 Istanbul
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationAnticoagulation therapy in acute coronary syndromes according to current guidelines
Acute management of ACS Anticoagulation therapy in acute coronary syndromes according to current guidelines Marcin Grabowski, Marcin Leszczyk, Andrzej Cacko, Krzysztof J. Filipiak, Grzegorz Opolski 1 st
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More information2010 ACLS Guidelines. Primary goals of therapy for patients
2010 ACLS Guidelines Part 10: Acute Coronary Syndrome Present : 內科 R1 鍾伯欣 Supervisor: F1 吳亮廷 991110 Primary goals of therapy for patients of ACS Reduce the amount of myocardial necrosis that occurs in
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationObjectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?
Objectives Acute Coronary Syndromes; The Nuts and Bolts Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Compare and contrast pathophysiology of unstable angina (UA), non-st segment elevation
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationEarly Management of Acute Coronary Syndrome
Early Management of Acute Coronary Syndrome Connie Hess, MD, MHS University of Colorado Division of Cardiology Acute Coronary Syndrome (ACS) A range of conditions associated with sudden imbalance in myocardial
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationAcute coronary syndrome (ACS) is a potentially
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD* ABSTRACT Acute coronary syndrome is a form of coronary artery disease and has a broad range of clinical presentations.
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationA Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 1
More informationThe PAIN Pathway for the Management of Acute Coronary Syndrome
2 The PAIN Pathway for the Management of Acute Coronary Syndrome Eyal Herzog, Emad Aziz, and Mun K. Hong Acute coronary syndrome (ACS) subsumes a spectrum of clinical entities, ranging from unstable angina
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Vorapaxar for the secondary prevention of atherothrombotic events after myocardial infarction Draft scope (pre-referral)
More informationThe Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI
The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish
More informationCase Challenges in ACS The Very Elderly in the Cath Lab
Case Challenges in ACS The Very Elderly in the Cath Lab Sameh Salama, MD, FSCAI Professor of Cardiology, Cairo University 86 yrs old male IDDM (controlled on insulin and oral hypoglycemics) Hypertensive
More information4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationGUIDELINE 14 ACUTE CORONARY SYNDROMES
AUSTRALIAN RESUSCITATION COUNCIL GUIDELINE 14 ACUTE CORONARY SYNDROMES OVERVIEW AND SUMMARY As a part of the International Liaison Committee on Resuscitation (ILCOR) process that led to the International
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :
More informationDisclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None
Inpatient Management of Non-ST Elevation Acute Coronary Syndromes Edward McNulty MD, FACC Assistant Clinical Professor UCSF Director, SF VAMC Cardiac Catheterization Laboratory Disclosures None New Guidelines
More information2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Developed in Collaboration with American College of Emergency Physicians and Society for Cardiovascular Angiography and
More informationRecognizing the High Risk NSTEMI Patient for Early Appropriate Therapy
Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS
More informationACCP Cardiology PRN Journal Club. 24 May 2018
ACCP Cardiology PRN Journal Club 24 May 2018 Mentor Bio Dr. James Coons is an associate professor at the University of Pittsburgh School of Pharmacy and clinical specialist at UPMC. Additionally, he is
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationUnstable angina and NSTEMI
Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationST-elevation myocardial infarctions (STEMIs)
Guidelines for Treating STEMI: Case-Based Questions As many as 25% of eligible patients presenting with STEMI do not receive any form of reperfusion therapy. The ACC/AHA guidelines highlight steps to improve
More informationMore than 1 million percutaneous coronary intervention
n report n Percutaneous Coronary Intervention: Assessing Coronary Vascular Risk Associated With Bare-Metal and Drug-Eluting Stents Sarah A. Spinler, PharmD, FCCP, BCPS (AQ Cardiology) Abstract Percutaneous
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationSTEMI: Newer Aspects in Pharmacological Treatment
CHAPTER 14 STEMI: Newer Aspects in Pharmacological Treatment P. C. Manoria, Pankaj Manoria Introduction ST elevation myocardial infarction (STEMI) commonly results from disruption of a vulnerable plaque
More informationAcute Coronary Syndromes. January 9, 2013 Chris Chiles M.D. FACC
Acute Coronary Syndromes January 9, 2013 Chris Chiles M.D. FACC Disclosures None- not even a breakfast burrito from a drug company Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes* 1.57
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationThe following is a transcript from a multimedia activity. Interactivity applies only when viewing the activity online.
Presentation 1 The following is a transcript from a multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by an educational grant from Daiichi Sankyo
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More information10 Steps to Managing Non-ST Elevation ACS
Pathophysiology of Acute Coronary Syndromes and Potential Pharmacologic Interventions Acute Coronary Syndrome 4. Downstream from thrombus myocardial ischemia/necrosis (Beta-blockers, Nitrates etc) 3. Activation
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More information